Skip to main content
Erschienen in: European Radiology 6/2017

17.10.2016 | Breast

Suspicious breast calcifications undergoing stereotactic biopsy in women ages 70 and over: Breast cancer incidence by BI-RADS descriptors

verfasst von: Lars J. Grimm, David Y. Johnson, Karen S. Johnson, Jay A. Baker, Mary Scott Soo, E. Shelley Hwang, Sujata V. Ghate

Erschienen in: European Radiology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To determine the malignancy rate overall and for specific BI-RADS descriptors in women ≥70 years who undergo stereotactic biopsy for calcifications.

Methods

We retrospectively reviewed 14,577 consecutive mammogram reports in 6839 women ≥70 years to collect 231 stereotactic biopsies of calcifications in 215 women. Cases with missing images or histopathology and calcifications associated with masses, distortion, or asymmetries were excluded. Three breast radiologists determined BI-RADS descriptors by majority. Histology, hormone receptor status, and lymph node status were correlated with BI-RADS descriptors.

Results

There were 131 (57 %) benign, 22 (10 %) atypia/lobular carcinomas in situ, 55 (24 %) ductal carcinomas in situ (DCIS), and 23 (10 %) invasive diagnoses. Twenty-seven (51 %) DCIS cases were high-grade. Five (22 %) invasive cases were high-grade, two (9 %) were triple-negative, and three (12 %) were node-positive. Malignancy was found in 49 % (50/103) of fine pleomorphic, 50 % (14/28) of fine linear, 25 % (10/40) of amorphous, 20 % (3/15) of round, 3 % (1/36) of coarse heterogeneous, and 0 % (0/9) of dystrophic calcifications.

Conclusions

Among women ≥70 years that underwent stereotactic biopsy for calcifications only, we observed a high rate of malignancy. Additionally, coarse heterogeneous calcifications may warrant a probable benign designation.

Key Points

Cancer rates of biopsied calcifications in women ≥70 years are high
Radiologists should not dismiss suspicious calcifications in older women
Coarse heterogeneous calcifications may warrant a probable benign designation
Literatur
1.
Zurück zum Zitat Hartman M, Drotman M, Arleo EK (2015) Annual screening mammography for breast cancer in women 75 years old or older: to screen or not to screen. AJR Am J Roentgenol 204:1132–1136CrossRefPubMed Hartman M, Drotman M, Arleo EK (2015) Annual screening mammography for breast cancer in women 75 years old or older: to screen or not to screen. AJR Am J Roentgenol 204:1132–1136CrossRefPubMed
2.
Zurück zum Zitat Galit W, Green MS, Lital KB (2007) Routine screening mammography in women older than 74 years: a review of the available data. Maturitas 57:109–119CrossRefPubMed Galit W, Green MS, Lital KB (2007) Routine screening mammography in women older than 74 years: a review of the available data. Maturitas 57:109–119CrossRefPubMed
3.
Zurück zum Zitat Hurria A, Leung D, Trainor K, Borgen P, Norton L, Hudis C (2003) Factors influencing treatment patterns of breast cancer patients age 75 and older. Crit Rev Oncol Hematol 46:121–126CrossRefPubMed Hurria A, Leung D, Trainor K, Borgen P, Norton L, Hudis C (2003) Factors influencing treatment patterns of breast cancer patients age 75 and older. Crit Rev Oncol Hematol 46:121–126CrossRefPubMed
5.
Zurück zum Zitat Malmgren JA, Parikh J, Atwood MK, Kaplan HG (2014) Improved prognosis of women aged 75 and older with mammography-detected breast cancer. Radiology 273:686–694CrossRefPubMed Malmgren JA, Parikh J, Atwood MK, Kaplan HG (2014) Improved prognosis of women aged 75 and older with mammography-detected breast cancer. Radiology 273:686–694CrossRefPubMed
6.
Zurück zum Zitat Tabar L, Vitak B, Chen TH et al (2011) Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 260:658–663CrossRefPubMed Tabar L, Vitak B, Chen TH et al (2011) Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 260:658–663CrossRefPubMed
7.
Zurück zum Zitat Kemeny MM, Peterson BL, Kornblith AB et al (2003) Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 21:2268–2275CrossRefPubMed Kemeny MM, Peterson BL, Kornblith AB et al (2003) Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 21:2268–2275CrossRefPubMed
8.
Zurück zum Zitat Lee CH, Dershaw DD, Kopans D et al (2010) Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol 7:18–27CrossRefPubMed Lee CH, Dershaw DD, Kopans D et al (2010) Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol 7:18–27CrossRefPubMed
9.
Zurück zum Zitat Smith-Bindman R, Kerlikowske K, Gebretsadik T, Newman J (2000) Is screening mammography effective in elderly women? Am J Med 108:112–119CrossRefPubMed Smith-Bindman R, Kerlikowske K, Gebretsadik T, Newman J (2000) Is screening mammography effective in elderly women? Am J Med 108:112–119CrossRefPubMed
10.
Zurück zum Zitat Kerlikowske K, Salzmann P, Phillips KA, Cauley JA, Cummings SR (1999) Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness. JAMA 282:2156–2163CrossRefPubMed Kerlikowske K, Salzmann P, Phillips KA, Cauley JA, Cummings SR (1999) Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness. JAMA 282:2156–2163CrossRefPubMed
13.
Zurück zum Zitat Oeffinger KC, Fontham ET, Etzioni R et al (2015) Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA 314:1599–1614CrossRefPubMedPubMedCentral Oeffinger KC, Fontham ET, Etzioni R et al (2015) Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA 314:1599–1614CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Anderson WF, Pfeiffer RM, Dores GM, Sherman ME (2006) Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 15:1899–1905CrossRefPubMed Anderson WF, Pfeiffer RM, Dores GM, Sherman ME (2006) Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 15:1899–1905CrossRefPubMed
16.
17.
Zurück zum Zitat Bombonati A, Sgroi DC (2011) The molecular pathology of breast cancer progression. J Pathol 223:307–317CrossRefPubMed Bombonati A, Sgroi DC (2011) The molecular pathology of breast cancer progression. J Pathol 223:307–317CrossRefPubMed
18.
Zurück zum Zitat Erbas B, Provenzano E, Armes J, Gertig D (2006) The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat 97:135–144CrossRefPubMed Erbas B, Provenzano E, Armes J, Gertig D (2006) The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat 97:135–144CrossRefPubMed
19.
Zurück zum Zitat Alvarado M, Ozanne E, Esserman L. Overdiagnosis and overtreatment of breast cancer. Am Soc Clin Oncol Educ Book 2012:e40–5 Alvarado M, Ozanne E, Esserman L. Overdiagnosis and overtreatment of breast cancer. Am Soc Clin Oncol Educ Book 2012:e40–5
20.
Zurück zum Zitat Hall FM (2014) Screening mammography guidelines: an alternative proactive approach. Radiology 273:646–651CrossRefPubMed Hall FM (2014) Screening mammography guidelines: an alternative proactive approach. Radiology 273:646–651CrossRefPubMed
21.
Zurück zum Zitat Spangler ML, Zuley ML, Sumkin JH et al (2011) Detection and classification of calcifications on digital breast tomosynthesis and 2D digital mammography: a comparison. AJR Am J Roentgenol 196:320–324CrossRefPubMed Spangler ML, Zuley ML, Sumkin JH et al (2011) Detection and classification of calcifications on digital breast tomosynthesis and 2D digital mammography: a comparison. AJR Am J Roentgenol 196:320–324CrossRefPubMed
22.
Zurück zum Zitat Kim SY, Kim HY, Kim EK, Kim MJ, Moon HJ, Yoon JH (2015) Evaluation of malignancy risk stratification of microcalcifications detected on mammography: a study based on the 5th edition of BI-RADS. Ann Surg Oncol 22:2895–2901CrossRefPubMed Kim SY, Kim HY, Kim EK, Kim MJ, Moon HJ, Yoon JH (2015) Evaluation of malignancy risk stratification of microcalcifications detected on mammography: a study based on the 5th edition of BI-RADS. Ann Surg Oncol 22:2895–2901CrossRefPubMed
23.
Zurück zum Zitat Ikeda DM, Hylton NM, Kuhl CK et al (2013) BI-RADS: mammography. In: D'Orsi CJ, Mendelson EB, Ikeda DM (eds) Breast imaging reporting and data system: ACR BI-RADS – breast imaging atlas. 5th ed. American College of Radiology, Reston, VA Ikeda DM, Hylton NM, Kuhl CK et al (2013) BI-RADS: mammography. In: D'Orsi CJ, Mendelson EB, Ikeda DM (eds) Breast imaging reporting and data system: ACR BI-RADS – breast imaging atlas. 5th ed. American College of Radiology, Reston, VA
25.
Zurück zum Zitat Grimm LJ, Johnson KS, Marcom PK, Baker JA, Soo MS (2015) Can breast cancer molecular subtype help to select patients for preoperative MR imaging? Radiology 274:352–358CrossRefPubMed Grimm LJ, Johnson KS, Marcom PK, Baker JA, Soo MS (2015) Can breast cancer molecular subtype help to select patients for preoperative MR imaging? Radiology 274:352–358CrossRefPubMed
26.
Zurück zum Zitat Grimm LJ, Zhang J, Mazurowski MA (2015) Computational approach to radiogenomics of breast cancer: Luminal A and luminal B molecular subtypes are associated with imaging features on routine breast MRI extracted using computer vision algorithms. J Magn Reson Imaging 42(4):902–907 Grimm LJ, Zhang J, Mazurowski MA (2015) Computational approach to radiogenomics of breast cancer: Luminal A and luminal B molecular subtypes are associated with imaging features on routine breast MRI extracted using computer vision algorithms. J Magn Reson Imaging 42(4):902–907
27.
Zurück zum Zitat Viera AJ, Garrett JM (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37:360–363PubMed Viera AJ, Garrett JM (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37:360–363PubMed
28.
Zurück zum Zitat Jiang M, Hughes DR, Duszak R Jr (2015) Screening mammography rates in the medicare population before and after the 2009 U.S. preventive services task force guideline change: an interrupted time series analysis. Womens Health Issues 25:239–245CrossRefPubMed Jiang M, Hughes DR, Duszak R Jr (2015) Screening mammography rates in the medicare population before and after the 2009 U.S. preventive services task force guideline change: an interrupted time series analysis. Womens Health Issues 25:239–245CrossRefPubMed
29.
Zurück zum Zitat Bent CK, Bassett LW, D'Orsi CJ, Sayre JW (2010) The positive predictive value of BI-RADS microcalcification descriptors and final assessment categories. AJR Am J Roentgenol 194:1378–1383CrossRefPubMed Bent CK, Bassett LW, D'Orsi CJ, Sayre JW (2010) The positive predictive value of BI-RADS microcalcification descriptors and final assessment categories. AJR Am J Roentgenol 194:1378–1383CrossRefPubMed
30.
Zurück zum Zitat Burnside ES, Ochsner JE, Fowler KJ et al (2007) Use of microcalcification descriptors in BI-RADS 4th edition to stratify risk of malignancy. Radiology 242:388–395CrossRefPubMed Burnside ES, Ochsner JE, Fowler KJ et al (2007) Use of microcalcification descriptors in BI-RADS 4th edition to stratify risk of malignancy. Radiology 242:388–395CrossRefPubMed
31.
Zurück zum Zitat Rosen EL, Baker JA, Soo MS (2002) Malignant lesions initially subjected to short-term mammographic follow-up. Radiology 223:221–228CrossRefPubMed Rosen EL, Baker JA, Soo MS (2002) Malignant lesions initially subjected to short-term mammographic follow-up. Radiology 223:221–228CrossRefPubMed
32.
Zurück zum Zitat Sickles EA (1999) Probably benign breast lesions: when should follow-up be recommended and what is the optimal follow-up protocol? Radiology 213:11–14CrossRefPubMed Sickles EA (1999) Probably benign breast lesions: when should follow-up be recommended and what is the optimal follow-up protocol? Radiology 213:11–14CrossRefPubMed
33.
Zurück zum Zitat Lazarus E, Mainiero MB, Schepps B, Koelliker SL, Livingston LS (2006) BI-RADS lexicon for US and mammography: interobserver variability and positive predictive value. Radiology 239:385–391CrossRefPubMed Lazarus E, Mainiero MB, Schepps B, Koelliker SL, Livingston LS (2006) BI-RADS lexicon for US and mammography: interobserver variability and positive predictive value. Radiology 239:385–391CrossRefPubMed
Metadaten
Titel
Suspicious breast calcifications undergoing stereotactic biopsy in women ages 70 and over: Breast cancer incidence by BI-RADS descriptors
verfasst von
Lars J. Grimm
David Y. Johnson
Karen S. Johnson
Jay A. Baker
Mary Scott Soo
E. Shelley Hwang
Sujata V. Ghate
Publikationsdatum
17.10.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 6/2017
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-016-4617-7

Weitere Artikel der Ausgabe 6/2017

European Radiology 6/2017 Zur Ausgabe

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.